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Abstract
Background: It is recommended that young child contacts of sputum smear positive tuberculosis cases receive
isoniazid preventive therapy (IPT) but reported adherence is low and risk factors for poor adherence in children are
largely unknown.
Methods: We prospectively determined rates of IPT adherence in children < 5 yrs in an Indonesian lung clinic.
Possible risk factors for poor adherence, defined as ≤3 months prescription collection, were calculated using
logistic regression. To further investigate adherence barriers in-depth interviews were conducted with caregivers of
children with good and poor adherence.
Results: Eighty-two children eligible for IPT were included, 61 (74.4%) of which had poor adherence. High
transport costs (OR 3.3, 95% CI 1.1-10.2) and medication costs (OR 20.0, 95% CI 2.7-414.5) were significantly
associated with poor adherence in univariate analysis. Access, medication barriers, disease and health service
experience and caregiver TB and IPT knowledge and beliefs were found to be important determinants of
adherence in qualitative analysis.
Conclusion: Adherence to IPT in this setting in Indonesia is extremely low and may result from a combination of
financial, knowledge, health service and medication related barriers. Successful reduction of childhood TB urgently
requires evidence-based interventions that address poor adherence to IPT.
Background
Increased risk of infection by Mycobacterium tuberculo-
sis among children in contact with a sputum smear
positive tuberculosis case is well documented [1-4].
Further, risk of progression to disease following infec-
tion is particularly high in young children and disease is
often severe and disseminated [3,4]. Therefore the
WHO recommends routine contact tracing and screen-
ing of all child contacts < 5 years followed by six to
nine months of isoniazid preventive therapy (IPT) in
those where active disease is ruled out [5]. IPT is safe
and effective; side effects in children are extremely rare
[6-8] and efficacy is over 90% when taken correctly [9].
Nevertheless this recommendation is rarely put in to
practice in high burden countries and, where IPT is
initiated, adherence is reportedly poor [10,11] and little
is known regarding associated adherence barriers
[10,12]. Knowledge of such barriers is necessary for tar-
geted interventions.
Indonesia is among the high burden countries [13]
that support active contact tracing and IPT as part of
their national TB program. In this setting such action
has great potential; a recent study from West Java found
51% of actively screened children aged < 9 yrs living
with a sputum smear positive case were positive for TB
infection.(Rutherford et al. In press) Yet IPT is rarely
implemented and current services are centralised to hos-
pitals and specialised clinics. No data are available on
adherence levels or associated barriers, with respect to
IPT for child case contacts in Indonesia.
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and risk factors for poor adherence to IPT in a cohort
of actively screened Indonesian children < 5 yrs living
with a sputum smear positive adult TB case.
Methods
Setting and participants
This sub-study was conducted between April 2009 and
September 2010 as part of a larger investigation evaluat-
ing tools for the diagnosis of latent tuberculosis infec-
tion (LTBI).(Rutherford et al. In press) Recruitment was
conducted at a community lung clinic in Bandung,
Indonesia where all newly diagnosed sputum smear and
chest x-ray (CXR) positive adult TB patients (≥15 yrs)
with one or more child contacts (household member for
at least 3 months; 6 months-9 years old) were invited to
bring their children to the clinic to undergo screening.
Children who had been diagnosed with TB in the pre-
vious year, or whose index case had at least one month
of anti-tuberculosis medication, were excluded.
Screening process
Following informed consent, children were clinically
assessed by the study nurse for TB related symptoms.
LTBI was evaluated by Quantiferon Gold In-tube assay
according to manufactures guidelines, and the tubercu-
lin skin test (TST). Children positive for infection by
either test underwent a CXR and a decision was made
by a local paediatrician regarding anti-tuberculosis treat-
ment. Children < 5 years who were screened and cleared
of disease, were placed on six months IPT in accordance
with WHO guidelines and included in this study [5].
Data collection
Baseline information was gathered from the child’sc a r e -
giver in their preferred language, including: child demo-
graphics and health indictors; disease characteristics of the
TB case; household and social factors including socio-eco-
nomic indicators; and barriers to IPT adherence as
hypothesised in the literature. IPT was unsupervised and
required caregivers to collect monthly prescriptions which
could only be obtained at the study clinic. The first pre-
scription was given directly after clinical assessment. Iso-
niazid (INH), in powder form, could then be purchased
from the clinic or any private pharmacy. Transportation
and medication costs were not subsidised. Attendance at
each prescription collection was recorded onto a stan-
darised form by study personnel. Levels of adherence were
defined as: poor adherence: ≤3 months prescription collec-
tion, good adherence: ≥4 months prescription collection.
During monthly prescription collection caregivers were
questioned about TB related symptoms, medication cost
and possible side effects or other difficulties related to
medication consumption.
Qualitative component
Caregivers were purposefully selected to represent chil-
dren with good adherence (n = 5) and poor-adherence (n
= 7). In-depth home-based interviews investigated knowl-
edge of TB aetiology and transmission, the purpose for
IPT, TB and IPT beliefs, barriers and facilitators to IPT,
and desired program improvements. Interviews were
conducted by an experienced qualitative researcher in a
language of the participant’s choice and lasted between
1-1.5 hrs. They were digitally recorded and transcribed
verbatim except where caregivers (n = 3) refused; for
these interviews detailed notes were taken. Transcribed
interviews were translated into English for analysis.
Data analysis
Quantitative data were double entered into ACCESS and
checked for errors. Adherence status was assessed
according to child demographics and TB case character-
istics using an extended Wilcoxon rank sum test. Risk
factors for poor adherence were investigated using uni-
variate and multivariate logistic regression modelling.
Confounding variables were selected for inclusion in
multivariate analysis using change in estimate methodol-
ogy [14]. Data analysis was conducted using STATA
version 11. Thematic coding was used to analyse the
qualitative interviews.
Ethical clearance was provided by the ethical commit-
tee, Faculty of Medicine, Universitas Padjadjaran.
Results
Of the 260 children recruited for the main study cohort
150 were aged < 5 yrs. Active TB was excluded in 82
children who were then enrolled into this sub-study.
The average age was 26.5 months (range 5-59), 49%
were male and the majority had evidence of a BCG vac-
cination (77%). Most children were asymptomatic (68%)
and LTBI negative (85%).
Quantitative analysis
Overall 21/82 (25.6% 95% CI 16.6-36.4) and 61/82
(74.4% 95% CI 63.6-83.4) children had good adherence
and poor adherence respectively. There was no signifi-
cant difference between children with good or poor
adherence with regards to demographic or TB case fac-
tors (Table 1). The average number of months a pre-
scription was collected was 2.5 (95% CI 2.1-2.9). Overall
adherence was poor and polarised with caregivers either
not returning after collection of the first prescription
(51%) or completing the entire course of treatment
(17%) (Figure 1).
For barriers related to medication consumption; hav-
ing medication related problems was seen more fre-
quently in those with poor adherence, while older age
was more commonly encountered in those with good
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univariate analysis (Table 2). For barriers related to
medication collection higher transport costs to the
clinic (OR 3.3 95% CI 1.1-10.2) and higher medication
costs (OR 20.0 95% CI 2.7-414.5) were significantly
associated with an increased risk of poor adherence.
Children with good adherence tended to be from a
household with a higher socio-economic status as esti-
mated by a household income index (total monthly
household income divided by number of household
members) but this did not reach statistical significance.
Qualitative analysis
Caregivers interviewed for the qualitative component of
this research were predominantly the child’sm o t h e r
(83%) and were aged 26 to 42 years. The children’s aver-
age age was 2.3 years and 69% were female. Four domi-
nant themes were identified. Quotes illustrating these
themes are presented in table 3.
Access
Financial access and distance were frequently mentioned
by all respondents as barriers to IPT and resulted
directly in poor adherence. Travel cost was the primary
access concern and distance as a barrier was frequently
mentioned in relation to higher travel costs. For
improvements to the existing IPT program, physical
access was most often suggested; most respondents sug-
gested IPT should be supplied at the peripheral health
clinics to reduce travel cost and distance.
Medication-related barriers
Medication costs were sighted as marginal compared
with other costs involved with IPT, particularly trans-
p o r t .H o w e v e r ,w h e r et w oo rm o r ec h i l d r e nf r o mt h e
Table 1 Demographic, clinical and TB case details
Variable Good adherence
N = 21 (%)
Poor adherence
N = 61 (%)
P-value*
Sex
Male 11 (52) 29 (48) 0.70
Female 10 (48) 32 (52)
BCG Scar
Yes 17 (81) 46 (75) 0.41
No 3 (14) 7 (11)
Unknown 1 (5) 8 (16)
LTBI at baseline
Positive 3 (14) 9 (15) 0.96
Negative 18 (86) 52 (85)
Relationship to TB case
Child 16 (76) 43 (70) 0.62
Other 5 (24) 18 (30)
Sputum smear positivity of contact
3 plus 8 (38) 19 (31) 0.79
2 plus 5 (24) 15 (25)
1 plus 4 (19) 19 (31)
Scanty 4 (19) 8 (13)
*Trends calculated by an extension of the Wilcoxon rank-sum test
Figure 1 Distribution of number of months IPT prescription collected.
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more problematic. All respondents mentioned difficulty
in medication administration due to the bitter taste of
INH. Respondents with poor adherence mentioned per-
sonal experiences (Table 3) while respondents with
good adherence spoke only in terms of others, expres-
sing a feeling of being fortunate that their children took
the medication. Both groups mentioned medication side
effects. The absence of side effects acted as a facilitator
and only children with poor adherence experienced side
effects.
Disease and health service experience
Respondents’ own TB experiences facilitated adherence;
respondents with good adherence mentioned a desire
for their children to avoid similar disease experiences
and expressed confidence in the anti-TB medication
they received (Table 3). Such experiences were not
described by respondents with poor adherence. Respon-
dents with good adherence frequently mentioned
favourable health service experiences, while bad experi-
ences with the health service was noted by respondents
with poor adherence and included: fear of staff; lack of
or incorrect information provision regarding IPT dura-
tion and purpose; and long waiting times.
Knowledge and beliefs
Knowledge of TB disease aetiology and transmission was
low among respondents with poor adherence, while all
respondents with good adherence showed correct TB
knowledge and an understanding of IPT. Regarding
beliefs, respondents with good adherence displayed a
desire for health, a preference for prevention over cure
and relief at the protection IPT offered. Respondents
with poor adherence commonly mentioned that the
child was healthy, and such reasoning aided in decisions
Table 2 Risk factors for poor adherence
Variable Good adherence
N = 21 (%)
Poor adherence N = 61 (%) OR (95% CI) P-value
Medication consumption barriers
Age (months)
0-24 9 (43) 30 (49) 1
25-60 12 (57) 31 (51) 0.78 (0.29-2.11) 0.62
Symptoms at baseline
No 14 (67) 42 (69) 1
Yes 7 (33) 19 (31) 0.90 (0.31-2.60) 0.85
Experienced side effects
No 17 (81) 15 (88) 1
Yes 4 (19) 2 (12) 1.76 (0.28-11.04) 0.54
Experienced any problem
No 18 (86) 15 (79) 1
Yes 3 (14) 4 (21) 1.60 (0.31-8.30) 0.58
Medication collection barriers
Income index (Rupiah)
0-100,000 1 (6) 8 (16) 1
> 100,000 17 (94) 42 (84) 0.30 (0.04-2.66) 0.29
Travel time to clinic (minutes)
0-30 11 (52) 33 (54) 1
> 30 10 (48) 28 (56) 0.93 (0.35-2.52) 0.89
Transport cost (Rupiah)
0-10,000 16 (76) 30 (49) 1
> 11,000 5 (23) 31 (51) 3.31 (1.08-10.16) 0.04
Medication cost (Rupiah)*
0-9,000 0 (0) 8 (50) 1
> 10000 2 (100) 8 (50) 20.00 (2.74-414.45) 0.00
* 0.5 used in place of 0 to calculate OR.
Indonesian Rupiah (IRP) 10,000 = 1USD
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adherence mentioned the need to give medication
despite their child’s current healthy status.
Discussion
In this prospective study of IPT adherence and asso-
ciated barriers in Indonesian children, only 26% of chil-
dren collected their medication prescription four or
more times. Indeed, 51% of all children did not return
to the clinic after the first month of medication pre-
scription. Such poor adherence is not unique. Research
in TB endemic settings in South Africa found adherence
rates for children < 5 years prescribed six months IPT
to be between 15-28% [10,11]. In Australia IPT adher-
ence rates among six-year-old children were between
54-74% [15] and in Brazil only 53% of all household
contacts completed IPT with 29% being immediately
lost to follow-up [16].
While limited by the size of the main study cohort,
quantitative analysis did indicate possible risk factors for
p o o ra d h e r e n c et oI P T .T h e s ew e r ep r e d o m i n a t e l y
related to financial barriers for medication collection
including cost of medication and transport, and low
socio-economic status. Transport cost as a barrier was
also frequently mentioned in the qualitative interviews.
Financial barriers to IPT adherence have been found
elsewhere. In Brazil TB household contacts prescribed
IPT, who took two buses to reach the study clinic were
1.8 (95% CI 1.01-3.3) times as likely to be non-adherent
compared to those who took only one bus. Authors
attributed this to an increase in transport costs [16].
Reduction of cost barriers through provision of IPT ser-
vices at peripheral health centres was a dominant pro-
posed solution in qualitative interviews.
Quantitative analysis suggested that side effects and
other treatment problems might be associated with poor
adherence. The importance of side effects was also a
theme that emerged from the qualitative interviews. The
negative effect of side effects has been sited elsewhere.
In Tanzania 14% of HIV positive patients initiated on
IPT did not complete therapy due to minor side effects,
[17] in Australia 23/32 patients who experienced minor
side effects stopped therapy [18] and in Thailand 10/72
HIV positive patients who missed more than one month
of IPT did so because of the perceived side effects of
INH [19].
We found older age to facilitate IPT adherence. This
has been reported elsewhere [12,15]. A South African
study found older children were more likely to complete
treatment. Authors postulated that difficulty in medica-
tion consumption explained this finding. Our study’s
qualitative findings support this; caregivers frequently
expressed that difficulties in medication administration
was a significant barrier. Ease of medication administra-
tion is especially important where drug regimens are
lengthy in duration and for prevention only.
From qualitative interviews IPT knowledge and health
beliefs were found to be important. Caregivers of chil-
dren with good adherence frequently mentioned a desire
for health while caregivers of children with poor adher-
ence often expressed a belief that IPT is unnecessary for
healthy children. Similarly, in Australia, from interviews
Table 3 Example quotes for qualitative themes
Theme Respondent
type
Respondent
characteristics
Quote
Access Good
adherence
Mother 30 yrs Even though I have to buy it (medication) myself, it won’t cost me too much because
the medicine alone is 20,000 Rp It doesn’t cost much.... the fare costs more than the
medicine.
Medication-related
barriers
Good
adherence
Mother 30 yrs It doesn’t happen with my kid. Whenever I tell her to take the medicine she does. But I
don’t know if I only gave her the powder without mixing it so she doesn’t taste the
bitterness. I worry she wouldn’t take it if she knows it was bitter
Poor
adherence
Disease and health
service experience
Good
adherence
Mother 30 yrs I also felt the benefits of the therapy.... I had constant coughing for 2 months and then it
stopped after medication
Poor
adherence
Mother 30 yrs Because I was afraid she’s (nurse) going to be angry with me. I was afraid she would
think I didn’t prioritize it.
Poor
adherence
Mother 41 yrs The nurses there didn’t tell (the child’s) parents that the therapy must be done for 6
months. (The child’s) father assumed due to a negative result (TST) the therapy didn’t
need to be continued
Knowledge and beliefs Good
adherence
Mother 26 yrs I just wanted (my child) to start therapy immediately because I wanted (my child) to be
healthy quickly... So I can stop being worried that something bad would happen to (my
child) because there’s already preventive medication so I feel secure
Poor
adherence
Mother 42 yrs I didn’t have much time, I had to go here and there... I wasn’t concentrating on that (IPT)
because I thought (the child) was healthy anyway
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believed their child required therapy [15] while in South
Africa reduced risk perception was commonly displayed
by parents of non-adherent children [10].
This study has several limitations. The relatively small
size limits multivariate analysis and strong inferences
are restricted. However, the addition of a qualitative
component strengthened conclusions supporting key
quantitative findings. Adherence levels could only be
measured by whether monthly prescriptions were col-
lected and it cannot be determined whether the medica-
tion was actually bought and how much was
administered to the child. However it seems reasonable
to assume that most caregivers who made the effort to
collect their prescription would also purchase and
administer the medication, at least after the first month.
It is possible that INH was acquired by caregivers at a
peripheral health care centre resulting in misclassifica-
tion and an underestimation of adherence rates. How-
ever for this to happen caregivers would have to seek
further screening at the peripheral health care centre
which seems unlikely. Further, on-going research at per-
ipheral health care centres in this setting shows IPT is
very rarely prescribed as a treatment option. Finally, this
study was conducted in a single setting, limiting general-
izability. Nevertheless the study site is a primary tuber-
culosis and lung disease referral clinic and the children
are likely representative of child case contacts in the
city. Further, all eligible child case contacts from conse-
cutively diagnosed sputum smear positive adult TB
cases were prospectively and actively screened, reducing
selection bias that may exist where only passively
screened children initiated on IPT are investigated [10].
Conclusion
This study highlights poor adherence as a major pro-
blem to effective IPT programs in Bandung, Indonesia
and indicates financial barriers, poor knowledge, health
service failure and difficulty with medication consump-
tion as key barriers. Improving adherence to IPT among
child case contacts is crucial to reduce child TB related
mortality in high burden countries and to achieve Mil-
lennium Goal Four. Efforts to improve adherence levels
may include: improving access by disseminated IPT pro-
vision; increasing caregiver knowledge of the purpose of
IPT through education programmes; and making avail-
able affordable child-friendly INH. Such efforts may go
a significant way in increasing adherence to IPT in child
case contacts in this and similar settings. Research that
implements and evaluates interventions to increase
adherence levels is now required in high burden low
resource settings.
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